Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic
nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the
first morning void urine sample as an indicator.